Keji Pharmaceutical-B (02171) announced interim results. Loss attributable to parent company owners of 666.63 million yuan narrowed 11.52% year-on-year

According to Zhitong Finance App, Keji Pharmaceutical-B (02171) announced its 2026 interim results, with revenue of about 61.919 million yuan, up 21.5% year on year; adjusted net loss of 31.927 million yuan, a year-on-year narrowing of 55.53%; parent company owners should have accounted for a loss of 666.63 million yuan, a decrease of 11.52% year on year; loss per share was 0.13 yuan.

According to the announcement, the increase in earnings was mainly due to increased sales of Seckeiser®. The reduced adjusted net loss was mainly due to lower administrative expenses.